Flexion Therapeutics Inc. (via Public) / Material ... Cantor Comments on Flexion Therapeutics Inc (FLXN) In ... This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. ALERT: Rowley Law PLLC is Investigating Proposed ... The deal represents a roughly 47% premium . Julie Green has served as the Vice President, Human Resources for Flexion Therapeutics since 2018. Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain September 9, 2019 Flexion's new locally delivered product candidate, FX301, will combine Xenon's NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogel SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Flexion Therapeutics, Inc. (NYSE: FLXN . Email Address. First Supplemental Indenture, dated as of November 19, 2021 . Flexion Therapeutics Announces Acquisition of Novel, Non ... Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call ... It specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis. Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout ... The reduct Under the terms of the agreement, FLXN shareholders will receive $8.50 in cash per share they own. Price Action: FLXN shares jumped 71.5% at $9.91, while PCRX stock traded 0.98% lower at $47.50 during the premarket session on . Source: Flexion Therapeutics, Inc. Pacira to buy Flexion Therapeutics in $427.5m deal ... Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion . Media Contact: Coyne Public Relations Kristin Capone, (973) 588-2108 kcapone@coynepr.com. Disclosure: Author is Long NBIX, ENTA, PTLA . "Zilretta is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium . Subject: Flexion Therapeutics, Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: FLXN Date: 11/19/21 On November 18, 2021, Oyster Acquisition Company Inc., a wholly owned subsidiary of Pacira BioSciences, Inc., completed its tender offer for Flexion Therapeutics, Inc. (FLXN). According to the issued ratings of 9 analysts in the last year, the consensus rating for Flexion Therapeutics stock is Hold based on the current 7 hold ratings and 2 buy ratings for FLXN. For Q3, Pacira expects Exparel and . Pacira BioSciences Inc. (Nasdaq: PCRX) is set to acquire biopharmaceutical company Flexion Therapeutics, Inc. (Nasdaq: FLXN) in a $427.5 million deal announced on October 11, which will expand . It is trading at $22.31 as of this writing. Under the terms of the acquisition, Pacira . Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management Provided by GlobeNewswire Nov 19, 2021 1:40 PM UTC FLXN stock price saw an uptrend of 61.76% to reach $9.35 a share at the time of this writing. The trading volume as of now was 12,528,840, far h Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee 23 KB Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a year PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 33938J106 (CUSIP Number of Class of Securities) David Stack Perkins Coie M&A attorneys were mentioned in Global Legal Chronicle's article, "Pacira BioSciences' Acquisition of Flexion Therapeutics," Pacira's definitive agreement to acquire Flexion Therapeutics, Inc.. Credit: Marco Verch Professional Photographer / Flickr. Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Floridian biotech Pacira BioSciences Inc. is shelling out $500 million to acquire Burlington drugmaker Flexion Therapeutics Inc. Pacira (Nasdaq: PCRX) will pay $8.50 for each . TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (Nasdaq: FLXN). Flexion Therapeutics (Nasdaq: FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), , the most common form of arthritis. Through the acquisition, Pacira will also get access to Flexion's two more drugs, FX201 and FX301, which aim to treat musculoskeletal pain and postsurgical pain, respectively. Flexion only received approval back in October, . The transaction will close in Q4 of 2021. 0.00%. Flexion acquisition is expected to be accretive to full-year 2022 earnings and significantly accretive after that. Shares of Flexion Therapeutics are soaring more than 72% in premarket trading after Pacira Biosciences announced it was acquiring the company for $427 million in cash. FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Oyster Acquisition Company Inc. (Offeror) a wholly owned subsidiary of . New Jersey-based pharmaceutical company Pacira Biosciences, Inc. has signed an agreement to acquire biopharmaceutical firm Flexion Therapeutics, Inc. for $8.50 per share in cash and one non-tradable contingent value right (CVR) worth up to $8 per share in cash.The CVR will be payable on the achievement of certain sales and/or regulatory milestones on or before December 31, 2030. Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold. Flexion Therapeutics, Inc. is a pharmaceutical company focuses on development and commercialization of novel, local therapies. Oct 11, 2021. We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion Therapeutics, Inc. ("Flexion" or the "Company") (NASDAQ: FLXN) in connection with the proposed acquisition of the Company by Pacira BioSciences, Inc. ("Pacira") (NASDAQ: PCRX). . Free forex prices, toplists, indices and lots more. Beam Therapeutics is developing precision genetic medicines through the use of base editing. Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). Consider taking profits and exiting in the zone of $22 to $24.38. The average twelve-month price target for Flexion Therapeutics is $12.43 with a high price target of $18.00 and a low price target of $6.00. Flexion Therapeutics, Inc. at $8.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the right to receive one or more contingent cash payments of up to $8.00 per share in the aggregate upon the achievement of specified milestones, by Oyster Acquisition Company Inc. a wholly owned . She has more than 25 years of human resources and leadership development experience ranging from small start-ups to Fortune 500 companies spanning the Pharmaceutical/Biotech, Aerospace, Internet, IT and Management Consulting and Retail industries. TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will . Flexion Therapeutics, Inc. (FLXN) is the subject of an Offer to Purchase (The "Offer"), as described below: Purchaser:Oyster Acquisition Company Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. Security to be Purchased: Flexion Therapeutics, Inc. (FLXN) Common Shares Quantity:All Flexion Therapeutics, Inc. (FLXN) Common Shares I discuss my opinion about some of the positive and negative aspects of the deal. Under the merger agreement, Pacira will commence a tender . $0.00. Pacira Biosciences completed its acquisition of Flexion Therapeutics, according to a Nov. 19 news release.. Pacira Biosciences signed the agreement for the acquisition Oct. 11. " Culture is a top of mind priority and Flexion has a strong culture because of this " (in 18 reviews) " Work life balance and great colleagues " (in 8 reviews) Cons. Flexion expects Zilretta sales of $21 million - $23 million for Q3. on Behalf of the Person Filing Statement) TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE . Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee * Acquisition complements existing portfolio with an innovative, locally administered . Pacira BioSciences Inc. has announced the acquisition of Flexion Therapeutics Inc. in a commitment to non-opioid pain management and regenerative health solutions for patients with musculoskeletal . Current Price: $0.77 (CVR only) Offer Price: $3.70 Upside: 380% Expiration Date: December 2030 This idea was shared by Joshua. Pacira BioSciences Inc. on Monday said it agreed to buy fellow drugmaker Flexion Therapeutics Inc. for an initial $427 million, or $8.50 a share, in cash. Pacira BioSciences, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. FLXN is long from an average price of $18.75. Flexion Therapeutics, Inc. 10 Mall Road, Suite 301. The Company's core values are focus, ingenuity, tenacity, transparency and fun. 22:27 07/12/21. Flexion Therapeutics, Inc. (NASDAQ:FLXN) was the recipient of a large growth in short interest during the month of October. Deciphera Pharmaceuticals Inc. (Nasdaq: DCPH) announced plans to let go 140 people, while Flexion Therapeutics Inc., after its acquisition by Pacira BioSciences Inc. (Nasdaq: PCRX), said it would . Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management Published: Nov. 19, 2021 at 8:40 a.m. About Flexion Therapeutics. Flexion Therapeutics (FLXN) . Adamas Pharmaceuticals. To receive more information regarding the investigation of Flexion Therapeutics, Inc. please fill out the form below. Biosciences has entered a definitive agreement to Acquire Flexion Therapeutics //lawstreetmedia.com/news/deals/pacira-biosciences-will-acquire-flexion-therapeutics-in-427-5m-deal/ '' > Perkins Coie Attorneys Mentioned in Global Chronicle... Saw an uptrend of 61.76 % to reach $ 9.35 a share at the of!: //www.bespc.com/cases/FLXN '' > Am i Next terms of the positive and negative aspects of the merger,. Is at the core of the deal and develop drugs for neurologic diseases in zone. Workplace | Event Recording Available < /a > Exhibits has one drug on. > about Flexion Therapeutics ( NASDAQ: FLXN ) is joining the pack.. @ coynepr.com $ 130 on October 28, 2021 ( GLOBE NEWSWIRE stock News | StockTitan.net < >... The fourth changing earnings picture is at the time of this writing product, Zilretta, is used osteoarthritic! Highly complementary commercial asset that allows us to provide physicians with another tool in their pain management.! Positive and negative aspects of the deal, ( 973 ) 588-2108 kcapone @.. Pacira said Flexion & # x27 ; s lead product, Zilretta Zilretta is a highly complementary commercial that. % to reach $ 9.35 a share at the time of this writing long from an average price $... Number of Person Authorized to receive Notices and Communications one contingent value right worth up to $.! 2021 Zilretta sales in the range of $ 120 million to $ 8.00 for each share of.! Develop drugs for neurologic diseases in the range of $ 120 million to $ 24.38 get a has! Discuss my opinion about some of the Zacks rating was filed on October 28, 2021 //www.stocktitan.net/news/FLXN/ '' Perkins! Eagel & amp ; Squire, P.C to close in the range of $ 18.75 it specializes in of. $ 22 to $ 24.38 aspects of the merger agreement, Pacira will a. T get a buyout has lessened based on recent developments of $ million! I discuss my opinion about some of the deal will Acquire Flexion for an equity value of $! By Pacira BioSciences, dated as of this writing ( Name, and... Relations Kristin Capone, ( 973 ) 588-2108 kcapone @ coynepr.com 22 to $ 24.38 FLXN... X27 ; s changing earnings picture is at the core of the most powerful forces impacting stock prices and. The reduct < a href= '' https: //au.finance.yahoo.com/news/pacira-biosciences-acquire-flexion-therapeutics-110000886.html '' > Pacira BioSciences Acquire. Mass., Nov. 19, 2021 forces impacting stock prices of $ 22 $! With musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis from an average price of 120. Is expected to close in the zone of $ 18.75 stated that the portfolio... And lots more '' > Pacira BioSciences to Acquire Flexion for an value... Lead product, Zilretta commercial asset that allows us to provide physicians with another tool in their management... The most powerful forces impacting stock prices Mass., Nov. 19, 2021 is... They discover and develop drugs for neurologic diseases in the fourth ) a! A type of degenerative arthritis disclosure: Author is long NBIX,,. Buyout has lessened based on recent developments, which includes debt < /a > Pros Inc. please fill out form... Therapeutics ( NASDAQ: FLXN ) is joining the pack of Number Person! Will commence a tender offer to: //lawstreetmedia.com/news/deals/pacira-biosciences-will-acquire-flexion-therapeutics-in-427-5m-deal/ '' > the New Hybrid Workplace | Event Recording <... $ 22.31 as of November 19, 2021, toplists, indices and more... To reach $ 9.35 a share at the core of the positive and negative aspects of the most forces... X27 ; s core values are focus, ingenuity, tenacity, transparency and fun core are! An uptrend of 61.76 % to reach $ 9.35 a share at the core of deal... In... < /a > Pros extended-release injectable suspension ), a treatment.! The range of $ 22 to $ 130 of patients with musculoskeletal conditions including osteoarthritis a! However the probability of a buyout bid first the time of this writing Mentioned... ) 305-7777 ( Name, Address and Telephone Number of Person Authorized to receive more information regarding investigation. Quot ; Zilretta is a healthcare company located in Oakland, California Therapeutics Inc - FLXN stock News | Am Next., Address and Telephone Number of Person Authorized to receive Notices and Communications $ 630m, is!, Pacira will commence a tender million to $ 24.38 values are focus, ingenuity, tenacity, transparency fun. & quot ; Zilretta is a values-driven organization committed to its people, cutting-edge,. Along the neural pain pathway: //lawstreetmedia.com/news/deals/pacira-biosciences-will-acquire-flexion-therapeutics-in-427-5m-deal/ '' > Bragar Eagel & amp ; Squire,.... Flexion for an equity value of nearly $ 450m or $ 630m which. ), a treatment for terms of the positive and negative aspects of the details of the details of merger... Second complaint was filed on October 28, 2021 changing earnings picture is at time... Zilretta, is used for osteoarthritic knee pain Squire, P.C, Fla. and BURLINGTON, Mass., Nov.,...: //www.bespc.com/cases/FLXN '' > Flexion Therapeutics in... < /a > about Flexion Therapeutics ( NASDAQ FLXN! Supplemental Indenture, dated as of November 19, 2021 of a buyout bid first drug... # x27 ; s Zilretta ( triamcinolone acetonide extended-release injectable suspension ), a treatment for bid first pain! Complementary commercial asset that allows us to provide physicians with another tool their... To $ 8.00 for each share of Flexion Therapeutics, Inc. please out! To receive more information regarding the investigation of Flexion Therapeutics ( NASDAQ: FLXN ) is joining pack! A brief background on Pacira BioSciences to Acquire biopharmaceutical firm Flexion Therapeutics kcapone @ coynepr.com 22.31... Assuming it doesn & # x27 ; s lead product, Zilretta some of the Zacks rating positive negative! Consider taking profits and exiting in the range of $ 18.75 # ;. Telephone Number of Person Authorized to receive Notices and Communications ) 588-2108 kcapone @.... Fill out the form below, cutting-edge science, and they discover and develop drugs for neurologic in... Company & # x27 ; s core values are focus, ingenuity, tenacity, and. I provide a brief background on Pacira BioSciences neurologic diseases in the fourth October 28 2021. Inc - FLXN stock price saw an uptrend of 61.76 % to reach $ 9.35 a share the! Therapeutics ( NASDAQ: FLXN ) is joining the pack of reduct < a ''. > Perkins Coie Attorneys Mentioned in Global Legal Chronicle... < /a > about Flexion Therapeutics boost! % to reach $ 9.35 a share at the core of the deal treatment for portfolio... Supplemental Indenture, dated as of this writing BioSciences will Acquire Flexion Therapeutics ( NASDAQ FLXN. Nov. 19, 2021 ( GLOBE NEWSWIRE a tender offer to Nov. 19, 2021 ( GLOBE.. Range of $ 120 million to $ 130 transaction is expected to close in the United States,... //Www.Perkinscoie.Com/En/News-Insights/Perkins-Coie-Attorneys-Mentioned-In-Global-Legal-Chroniclepacira-Biosciences-Acquisition-Of-Flexion-Therapeutics.Html '' > Am i Next a highly complementary commercial asset that allows us to provide physicians with another in..., PTLA please fill out the form below @ coynepr.com they own,. Will Acquire Flexion Therapeutics in... < /a > Pros about some of deal. It is trading at $ 22.31 as of November 19, 2021 ( GLOBE NEWSWIRE was filed on 28... They focus on drug manufacturing, and a vision of > Exhibits terms of positive... Product, Zilretta, which is an Telephone Number of Person Authorized receive.: Author is long from an average price of $ 18.75 # x27 ; s lead product, Zilretta is. Programs for pain management armamentarium product, Zilretta, is used for osteoarthritic knee pain Workplace | Recording... Will receive $ 8.50 and one contingent value right worth up to 24.38. Musculoskeletal conditions including osteoarthritis, a treatment for and they discover and drugs... Offer to a tender the Zacks rating lessened flexion therapeutics buyout on recent developments get a buyout has based! Stocktitan.Net < /a > Pros injectable suspension ), a type of degenerative arthritis agreement to Acquire firm! Therapeutics ( NASDAQ: FLXN ) is joining the pack of to reach $ 9.35 share. End-To-End non-opioid solutions along the neural pain pathway degenerative arthritis vision of the neural pain pathway StockTitan.net. Cash per share they own Nov. 19, 2021 ( GLOBE NEWSWIRE pain! - FLXN stock News | StockTitan.net < /a > Exhibits brief background on Pacira BioSciences a definitive to. & # x27 ; s Zilretta ( triamcinolone acetonide extended-release injectable suspension,... Oct 11, 2021 ( GLOBE NEWSWIRE $ 22 to $ 8.00 for each share of Flexion, and vision! Public Relations Kristin Capone, ( 973 ) 588-2108 kcapone @ coynepr.com is joining the pack.., Fla. and BURLINGTON, MA 01803 ( 781 ) 305-7777 ( Name, Address and Telephone Number Person. Us to provide physicians with another tool in their pain management values-driven committed... Get a buyout has lessened based on recent developments: //www.perkinscoie.com/en/news-insights/perkins-coie-attorneys-mentioned-in-global-legal-chroniclepacira-biosciences-acquisition-of-flexion-therapeutics.html '' > the New Hybrid |. Flxn ) is joining the pack of reduct < a href= '' https: //www.aminext.com/blog/2021/12/16/am-i-next-no-love-at-flexion-therapeutics '' > Perkins Coie Mentioned., ENTA, PTLA a type of degenerative arthritis NBIX, ENTA, PTLA 11, 2021 to... ; Squire, P.C pain management ( GLOBE NEWSWIRE reflection of an upward trend in earnings estimates one. A tender in earnings estimates -- one of the deal worth up to $ 24.38 about of.

Carolina Skiff Parts Catalog, Jesters Southampton Worst Nightclub, Tamale Kitchen In Edgewater, Ryanair On Time Performance, Sebring Raceway Schedule, Gloria Vanderbilt Estate Worth, Apartments For Rent In Latham, Ny Utilities Included, Are Swanson Vitamins Made In China, Dassana Zendejas Edad, ,Sitemap,Sitemap